AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8678259 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 40
Study 8678259 — intervention group
Group type: COMPARATOR
Intervention: Tracheal tube
Number of subjects: 40
Study 2130002 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone 60-80 mg/kg/day intramuscularly for 5-7 days
Number of subjects: 55
Study 2130002 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol 50-80 mg/kg/day orally in 4 divided doses for 12-14 days
Number of subjects: 55
Study 371646 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous mexiletine (150 mg bolus injection)
Number of subjects: 16
Study 371646 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline (control)
Number of subjects: 16
Study 31535807 — intervention group
Group type: EXPERIMENTAL
Intervention: SpermActin Forte, 1 sachet of 10 g once a day for 180 days
Number of subjects: 80
Study 31535807 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 180 days
Number of subjects: 80
Study 31535807 — intervention group
Group type: EXPERIMENTAL
Intervention: SpermActin Forte
Number of subjects: 80
Study 29217455 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal contact lenses
Number of subjects: 20
Study 29217455 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal contact lenses with yellow filter (YF)
Number of subjects: 20
Study 29217455 — intervention group
Group type: COMPARATOR
Intervention: Monovision contact lenses without far prescription
Number of subjects: 20
Study 26433727 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid clozapine titration (started at 25-50 mg, increased by 50-100 mg/day)
Number of subjects: 0
Study 26433727 — intervention group
Group type: COMPARATOR
Intervention: Slow clozapine titration (started at 12.5-50 mg, increased by 25-50 mg/day)
Number of subjects: 0
Study 26433727 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid clozapine titration
Number of subjects: 0
Study 26433727 — intervention group
Group type: COMPARATOR
Intervention: Slow clozapine titration
Number of subjects: 0
Study 24673714 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose (SD) of enteric-coated mycophenolate sodium (1440 mg/day)
Number of subjects: 60
Study 24673714 — intervention group
Group type: COMPARATOR
Intervention: Low dose (LD) of enteric-coated mycophenolate sodium (1080 mg/day)
Number of subjects: 60
Study 24673714 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard dose (SD) of enteric-coated mycophenolate sodium
Number of subjects: 60
Study 24673714 — intervention group
Group type: COMPARATOR
Intervention: Low dose (LD) of enteric-coated mycophenolate sodium
Number of subjects: 60
Study 24673714 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SD and LD groups
Number of subjects: 60
Study 22530305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate (30 mg) with SNAC (1:5 ratio)
Number of subjects: 97
Study 22530305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate (30 mg) with SNAC (1:10 ratio)
Number of subjects: 97
Study 22530305 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibandronate (30 mg) with SNAC (1:20 ratio)
Number of subjects: 97
Study 22530305 — intervention group
Group type: COMPARATOR
Intervention: Approved oral Ibandronate tablet formulations (150 mg IBN)
Number of subjects: 97
Study 22530305 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing post-dose fasting duration from 15 to 30 min
Number of subjects: 97
Study 22530305 — intervention group
Group type: EXPERIMENTAL
Intervention: IBN/SNAC treatments
Number of subjects: 97
Study 20598044 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (cetrorelix)
Number of subjects: 112
Study 20598044 — intervention group
Group type: COMPARATOR
Intervention: GnRH agonist (buserelin)
Number of subjects: 112
Study 18613441 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative prophylactic irrigation around the pancreaticojejunostomy for 72 hours starting from postoperative day 1
Number of subjects: 50
Study 18613441 — intervention group
Group type: COMPARATOR
Intervention: Non-irrigation (control group)
Number of subjects: 50
Study 15752384 — intervention group
Group type: EXPERIMENTAL
Intervention: Paracetamol 4 g day(-1)
Number of subjects: 11
Study 15752384 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 12584786 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhubarb powder orally or by nasal feeding
Number of subjects: 40
Study 12584786 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment alone (Control)
Number of subjects: 40
Study 12584786 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhubarb treatment
Number of subjects: 40
Study 12584786 — intervention group
Group type: COMPARATOR
Intervention: Normal control group
Number of subjects: 40
Study 10550952 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic total extraperitoneal repair
Number of subjects: 50
Study 10550952 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein repair
Number of subjects: 50
Study 7583542 — intervention group
Group type: EXPERIMENTAL
Intervention: Endurance exercise training (bicycle ergometer at about 60% of maximal oxygen consumption for 30 minutes per day, 5 days per week for 8 weeks)
Number of subjects: 100
Study 7583542 — intervention group
Group type: EXPERIMENTAL
Intervention: Deconditioning (12 weeks after training)
Number of subjects: 100
Study 7583542 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise training)
Number of subjects: 100
Study 7583542 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term strenuous exercise
Number of subjects: 100
Study 2258297 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon Alfa‐2b (Intron A) administered at a low-dose regimen (1 million I.U. s.c. daily for 6 days with a 2-week interval between courses)
Number of subjects: 0
Study 2258297 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 6786074 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteine supplementation (77 mg/kg/24 h)
Number of subjects: 0
Study 6786074 — intervention group
Group type: COMPARATOR
Intervention: Control intravenous formulations
Number of subjects: 0
Study 29679529 — intervention group
Group type: EXPERIMENTAL
Intervention: Parenteral ω‐3 LC‐PUFAs (EPA and DHA)
Number of subjects: 90
Study 29679529 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinoleic (Baxter Medical AB)
Number of subjects: 90
Study 29679529 — intervention group
Group type: EXPERIMENTAL
Intervention: SMOFlipid (Fresenius Kabi)
Number of subjects: 90
Study 29679529 — intervention group
Group type: COMPARATOR
Intervention: None of the parenteral lipid emulsions
Number of subjects: 90
Study 28993871 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrrolate (IND/GLY) 27.5/15.6 μg twice daily
Number of subjects: 0
Study 28993871 — intervention group
Group type: COMPARATOR
Intervention: Umeclidinium/vilanterol (UMEC/VI) 62.5/25 μg once daily
Number of subjects: 0
Study 28993871 — intervention group
Group type: EXPERIMENTAL
Intervention: Indacaterol/glycopyrrolate (IND/GLY)
Number of subjects: 0
Study 28993871 — intervention group
Group type: COMPARATOR
Intervention: Umeclidinium/vilanterol (UMEC/VI)
Number of subjects: 0
Study 25039675 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide
Number of subjects: 416
Study 25039675 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 416
Study 25039675 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Number of subjects: 416
Study 25039675 — intervention group
Group type: COMPARATOR
Intervention: Exenatide vs Insulin
Number of subjects: 416
Study 25039675 — intervention group
Group type: COMPARATOR
Intervention: Exenatide vs Pioglitazone
Number of subjects: 416
Study 25039675 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 416
Study 23825411 — intervention group
Group type: EXPERIMENTAL
Intervention: Activation of the contralesional hippocampus and increased engagement of a distributed short‐term memory network in neocortex during an associative short‐term memory task.
Number of subjects: 2
Study 23825411 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact associative short‐term memory despite hippocampal dysfunction.
Number of subjects: 2
Study 22010409 — intervention group
Group type: COMPARATOR
Intervention: Occlusal stabilization splint (control group)
Number of subjects: 16
Study 22010409 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft occlusal splint (experimental group)
Number of subjects: 16
Study 19009634 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine (AZA) 2.0-2.5 mg/kg a day
Number of subjects: 77
Study 19009634 — intervention group
Group type: COMPARATOR
Intervention: Budesonide (BUD) 6-9 mg a day
Number of subjects: 77
Study 18812202 — intervention group
Group type: EXPERIMENTAL
Intervention: pTHr.HIVA DNA vaccine (0.5 mg or 2 mg) followed by MVA.HIVA (5 x 10^7) at weeks 8 and 12 (early boost) or weeks 20 and 24 (late boost)
Number of subjects: 0
Study 18812202 — intervention group
Group type: COMPARATOR
Intervention: pTHr.HIVA DNA vaccine (0.5 mg or 2 mg) followed by MVA.HIVA (5 x 10^7)
Number of subjects: 0
Study 16033861 — intervention group
Group type: EXPERIMENTAL
Intervention: Trisodium citrate 30%
Number of subjects: 291
Study 16033861 — intervention group
Group type: COMPARATOR
Intervention: Heparin 5000 U/ml
Number of subjects: 291
Study 12161521 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human GH
Number of subjects: 16
Study 12161521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 10094079 — intervention group
Group type: EXPERIMENTAL
Intervention: Week-long training program
Number of subjects: 179000
Study 10094079 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-week-long training program
Number of subjects: 179000
Study 7595793 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous bone grafting
Number of subjects: 20
Study 7595793 — intervention group
Group type: COMPARATOR
Intervention: No bone grafting
Number of subjects: 20
Study 2241335 — intervention group
Group type: EXPERIMENTAL
Intervention: St. Jude Medical prosthesis
Number of subjects: 182
Study 2241335 — intervention group
Group type: COMPARATOR
Intervention: Medtronic-Hall prosthesis
Number of subjects: 182
Study 99089 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulised sodium cromoglycate
Number of subjects: 14
Study 99089 — intervention group
Group type: COMPARATOR
Intervention: Nebulised water
Number of subjects: 14
Study 31804404 — intervention group
Group type: EXPERIMENTAL
Intervention: Controlled ventilation with muscle relaxants (MR)
Number of subjects: 64
Study 31804404 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous respiration (SP)
Number of subjects: 64
Study 30843263 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine 50 mg
Number of subjects: 16
Study 30843263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 28146560 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed texts (LF)
Number of subjects: 152
Study 28146560 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed texts (GF)
Number of subjects: 152
Study 28146560 — intervention group
Group type: EXPERIMENTAL
Intervention: Static tailored texts (ST)
Number of subjects: 152
Study 28146560 — intervention group
Group type: EXPERIMENTAL
Intervention: Adaptive tailored texts (TA)
Number of subjects: 152
Study 28146560 — intervention group
Group type: COMPARATOR
Intervention: Weekly drink self-tracking mobile assessment texts (MA)
Number of subjects: 152
Study 26201694 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 g/kg/h of glucose
Number of subjects: 16
Study 26201694 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution
Number of subjects: 16
Study 23958074 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 μg of oral T3 every 12 hours starting 20 minutes before anesthetic induction, for a total of 4 doses
Number of subjects: 100
Study 23958074 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 21362360 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide
Number of subjects: 47
Study 21362360 — intervention group
Group type: COMPARATOR
Intervention: Gliclazide
Number of subjects: 47
Study 19190958 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (20mg)
Number of subjects: 29
Study 19190958 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20mg)
Number of subjects: 29
Study 17141739 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 IU Syntocinon)
Number of subjects: 19
Study 17141739 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 15508663 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound imaging performed immediately before and after ET tube placement
Number of subjects: 59
Study 11422695 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass-ionomer cement (GIC)
Number of subjects: 117
Study 11422695 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite resin (CR)
Number of subjects: 117
Study 9773912 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic surfactant (EXOSURF Neonatal)
Number of subjects: 83
Study 9773912 — intervention group
Group type: COMPARATOR
Intervention: Air-treated control
Number of subjects: 83
Study 8153781 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of ketorolac orally
Number of subjects: 176
Study 8153781 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg of morphine intramuscularly
Number of subjects: 176
Study 8153781 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg of morphine intramuscularly
Number of subjects: 176
Study 8153781 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 176
Study 2894169 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide
Number of subjects: 502
Study 2894169 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 502
Study 2894169 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 502
Study 2894169 — intervention group
Group type: EXPERIMENTAL
Intervention: Moricizine
Number of subjects: 502
Study 2894169 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 502
Study 2894169 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide and Flecainide in patients who failed Imipramine or Moricizine
Number of subjects: 502
Study 2894169 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide, Flecainide, and Moricizine
Number of subjects: 502
Study 31398065 — intervention group
Group type: EXPERIMENTAL
Intervention: UCLA group (n = 25)
Number of subjects: 84
Study 31398065 — intervention group
Group type: EXPERIMENTAL
Intervention: UCLP group (n = 23)
Number of subjects: 84
Study 31398065 — intervention group
Group type: EXPERIMENTAL
Intervention: BCLP group (n = 22)
Number of subjects: 84
Study 31398065 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 14)
Number of subjects: 84
Study 31192549 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice group
Number of subjects: 22
Study 31192549 — intervention group
Group type: COMPARATOR
Intervention: Steamed buns group
Number of subjects: 22
Study 27548886 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg CoQ10 supplementation for 12 weeks
Number of subjects: 33
Study 27548886 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg CoQ10 supplementation for 12 weeks
Number of subjects: 33
Study 27548886 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 25516073 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation plus printed educational materials (PEM)
Number of subjects: 100
Study 25516073 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient navigation plus PEM
Number of subjects: 100
Study 25516073 — intervention group
Group type: COMPARATOR
Intervention: Printed educational materials (PEM)
Number of subjects: 100
Study 23314784 — intervention group
Group type: EXPERIMENTAL
Intervention: Full stimulation
Number of subjects: 32
Study 23314784 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 32
Study 23314784 — intervention group
Group type: COMPARATOR
Intervention: Sub-perception stimulation
Number of subjects: 32
Study 23314784 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall patient outcomes
Number of subjects: 32
Study 23314784 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety outcomes
Number of subjects: 32
Study 21598188 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed message
Number of subjects: 0
Study 21598188 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed message
Number of subjects: 0
Study 21598188 — intervention group
Group type: EXPERIMENTAL
Intervention: Present outcomes (gain, loss)
Number of subjects: 0
Study 21598188 — intervention group
Group type: COMPARATOR
Intervention: Absent outcomes (non-gain, non-loss)
Number of subjects: 0
Study 18706464 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumococcal vaccination
Number of subjects: 0
Study 18706464 — intervention group
Group type: COMPARATOR
Intervention: Younger healthy controls
Number of subjects: 0
Study 18706464 — intervention group
Group type: EXPERIMENTAL
Intervention: Older adults
Number of subjects: 0
Study 16968106 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonols derived from sea buckthorn ingested with oatmeal porridge
Number of subjects: 0
Study 16968106 — intervention group
Group type: EXPERIMENTAL
Intervention: Flavonols at two dosages in oatmeal porridge
Number of subjects: 0
Study 16968106 — intervention group
Group type: EXPERIMENTAL
Intervention: Sea buckthorn oil added to porridge
Number of subjects: 0
Study 14573316 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrocortisone (100 mg orally)
Number of subjects: 14
Study 14573316 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 11050369 — intervention group
Group type: EXPERIMENTAL
Intervention: Self Care intervention
Number of subjects: 226
Study 11050369 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 226
Study 9316439 — intervention group
Group type: EXPERIMENTAL
Intervention: IGF-I (10 micrograms.kg‐1.h‐1)
Number of subjects: 8
Study 9316439 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 8
Study 8476616 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine 0.1 mg/kg added to axillary block solution (AX)
Number of subjects: 0
Study 8476616 — intervention group
Group type: COMPARATOR
Intervention: Saline added to axillary block solution with morphine 0.1 mg/kg IV (CT)
Number of subjects: 0
Study 3090830 — intervention group
Group type: EXPERIMENTAL
Intervention: Asparaginase (ASNase)
Number of subjects: 14
Study 3090830 — intervention group
Group type: COMPARATOR
Intervention: High-dose cytosine arabinoside (HIDARAC)
Number of subjects: 14
Study 29502640 — intervention group
Group type: EXPERIMENTAL
Intervention: Elaborated reminder prompt
Number of subjects: 648
Study 29502640 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple reminder prompt
Number of subjects: 648
Study 29502640 — intervention group
Group type: COMPARATOR
Intervention: Usual practice control
Number of subjects: 648
Study 27441946 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-domestic violence ads with narrative exemplars promoting bystander awareness and intervention
Number of subjects: 0
Study 27441946 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-domestic violence ads without narrative exemplars featuring emotional self-efficacy appeal targeting bystanders
Number of subjects: 0
Study 27441946 — intervention group
Group type: EXPERIMENTAL
Intervention: Ads featuring a celebrity spokesperson
Number of subjects: 0
Study 25362169 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone (AM)
Number of subjects: 31
Study 25362169 — intervention group
Group type: COMPARATOR
Intervention: d-sotalol (DS)
Number of subjects: 31
Study 23952897 — intervention group
Group type: EXPERIMENTAL
Intervention: Primary care buprenorphine OST
Number of subjects: 15
Study 23952897 — intervention group
Group type: COMPARATOR
Intervention: Specialist facility buprenorphine OST
Number of subjects: 15
Study 23952897 — intervention group
Group type: COMPARATOR
Intervention: Specialist facility methadone OST
Number of subjects: 15
Study 20693725 — intervention group
Group type: EXPERIMENTAL
Intervention: Community engagement to activate a multiple-agency network
Number of subjects: 0
Study 20693725 — intervention group
Group type: COMPARATOR
Intervention: Support for individual agencies to implement depression QI
Number of subjects: 0
Study 18937675 — intervention group
Group type: EXPERIMENTAL
Intervention: Education programme delivered by trained peer advisers
Number of subjects: 83
Study 18937675 — intervention group
Group type: COMPARATOR
Intervention: Education programme delivered by specialist health professionals
Number of subjects: 83
Study 18937675 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 83
Study 18937675 — intervention group
Group type: COMPARATOR
Intervention: Health professionals
Number of subjects: 83
Study 16157900 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone 12 mg/m2
Number of subjects: 194
Study 16157900 — intervention group
Group type: COMPARATOR
Intervention: Mitoxantrone 5 mg/m2
Number of subjects: 194
Study 14521770 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-management program for hypertensive patients
Number of subjects: 0
Study 10953829 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy (omeprazole, tetracycline, metronidazole, bismuth subcitrate) for 7 days followed by OCA7 if failure
Number of subjects: 97
Study 10953829 — intervention group
Group type: EXPERIMENTAL
Intervention: OCA7 for 7 days followed by quadruple therapy if failure
Number of subjects: 97
Study 10953829 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost per case treated
Number of subjects: 97
Study 10953829 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost per case eradicated
Number of subjects: 97
Study 8840836 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 40 mg
Number of subjects: 768
Study 8840836 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 768
Study 1378147 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg
Number of subjects: 21
Study 1378147 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol 50 mg
Number of subjects: 21
Study 1378147 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 6392353 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular levonantradol 0.5 mg
Number of subjects: 20